Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV-058 Long-term Immunogenicity Follow-up
CTR20171371Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human papillomavirus type 16 L1 capsid protein antigen in Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), cervical adenocarcinoma in situ (AIS), human papillomavirus infection, sponsored by GSK. Started Dec 2017; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
Cervical Cancer (CC)cervical intraepithelial neoplasia (CIN)cervical adenocarcinoma in situ (AIS)human papillomavirus infection
Beyond the preview
Go deeper on CTR20171371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171371.